Invex Therapeutics Ltd (IXC:ASX) Investor Relations Material

Overview

Invex Therapeutics is a biopharmaceutical company that specializes in repurposing an existing drug, Exenatide, for the treatment of neurological conditions caused by, or related to, raised intracranial pressure. The company focuses on conditions such as Idiopathic Intracranial Hypertension (IIH), acute stroke, and traumatic brain injury. It has trademarked its repurposed Exenatide as Presendin™.

Frequently Asked Questions

What is Invex Therapeutics Ltd's ticker?

Invex Therapeutics Ltd's ticker is IXC

What exchange is Invex Therapeutics Ltd traded on?

The company's shares trade on the ASX stock exchange

Where are Invex Therapeutics Ltd's headquarters?

They are based in Subiaco, Australia

How many employees does Invex Therapeutics Ltd have?

There are 1-10 employees working at Invex Therapeutics Ltd

What is Invex Therapeutics Ltd's website?

It is https://invextherapeutics.com/

What type of sector is Invex Therapeutics Ltd?

Invex Therapeutics Ltd is in the Healthcare sector

What type of industry is Invex Therapeutics Ltd?

Invex Therapeutics Ltd is in the Biotechnology industry

Who are Invex Therapeutics Ltd's peers and competitors?

The following five companies are Invex Therapeutics Ltd's industry peers:

- OKYO Pharma Limited

- CymaBay Therapeutics

- Checkpoint Therapeutics, Inc.

- Bio-Gene Technology Limited

- Cytokinetics